Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biogen Inc. (BIIB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. As a Nasdaq-listed biotechnology company, Biogen uses these filings to report financial results, material events and governance matters that are important for investors evaluating its activities in neurology, rare diseases and immunology.
Recent Form 8-K filings show how Biogen communicates results of operations and financial condition, including quarterly earnings press releases and preliminary estimates of acquired in-process research and development, upfront and milestone expenses. The company explains that these expenses arise from collaboration and license agreements and are presented as a separate line item in its condensed consolidated statements of income. Other 8-K filings cover shareholder votes at the annual meeting, such as the election of directors and ratification of the independent registered public accounting firm.
Through this page, users can review Biogen’s SEC-reported information alongside Stock Titan’s AI-powered tools, which can help summarize lengthy filings and highlight key items such as collaboration-related charges, capital allocation decisions and governance outcomes. Investors interested in Biogen’s partnerships, pipeline investments and financial reporting practices can use these filings to understand how the company accounts for its research collaborations, including those involving antisense oligonucleotides, monoclonal antibodies and emerging modalities.
In addition to 8-Ks, this page can link to other Biogen filings available on EDGAR, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company provides more detailed discussion of its business, risk factors and financial statements. Together, these documents form the regulatory record that underpins fundamental analysis of BIIB.
Biogen Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 10,989,562 shares of Biogen common stock, representing 7.48% of the class. The filing shows Vanguard has sole voting power for 1,452,145 shares and sole dispositive power for 10,989,562 shares.
The Schedule 13G statement describes holdings across Vanguard business units and notes the reported interests include shares held for Vanguard funds and other managed accounts.
Biogen Inc. reported modestly higher quarterly revenue and stronger profits while outlining a sizable acquisition. For the three months ended March 31, 2026, revenue rose to $2.48 billion from $2.43 billion a year earlier, driven by multiple sclerosis, rare disease and anti-CD20 program revenue.
Net income attributable to Biogen increased to $319.5 million, up from $240.5 million, with diluted EPS improving to $2.15 from $1.64. Operating cash flow strengthened to $645.5 million, supporting a cash and cash equivalents balance of $3.38 billion and total assets of $29.48 billion.
Biogen also agreed to acquire Apellis Pharmaceuticals for $41.00 per share in cash, valuing the deal at about $5.6 billion, plus a contingent value right of up to $4.00 per share tied to SYFOVRE sales. The company plans to fund the purchase with roughly $3.6 billion of existing cash and marketable securities and about $2.0 billion in bank loans, aiming to add two approved immunology and rare disease products to its portfolio.
Biogen Inc. reported first quarter 2026 revenue of $2.48 billion, up 2% year-over-year, with GAAP diluted EPS of $2.15 (up 31%) and Non-GAAP diluted EPS of $3.57 (up 18%). Growth products collectively grew 12% year-over-year, led by LEQEMBI in‑market sales of $168 million, SKYCLARYS at $151 million, ZURZUVAE at $55 million, VUMERITY at $179 million, SPINRAZA at $374 million, and QALSODY at $33 million.
Biogen highlighted new positive data from late-stage programs, including litifilimab in cutaneous lupus and additional salanersen data in SMA, as well as strong LEQEMBI persistence and U.S. approval of the SPINRAZA High Dose Regimen. The company announced a proposed acquisition of Apellis Pharmaceuticals, expected to be accretive in 2027 and to materially increase Biogen’s Non-GAAP diluted EPS compounded annual growth rate through the end of the decade. Biogen also signed an agreement with TJ Biopharma for exclusive felzartamab rights in Greater China.
For full year 2026, Biogen now expects Non-GAAP diluted EPS between $14.25 and $15.25, excluding any Apellis impact, and anticipates total revenue will decline by a mid-single digit percentage versus 2025. The EPS outlook includes about $1.00 of acquired IPR&D charges tied to ongoing business development. Q1 2026 free cash flow was $594.3 million, and cash and cash equivalents were $3.38 billion as of March 31, 2026.
Biogen Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 9, 2026. Proposals include electing 10 directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and an advisory vote on executive pay.
The proxy highlights a late-stage pipeline and notes a 2026 merger agreement with Apellis Pharmaceuticals, expected to add EMPAVELI and SYFOVRE and expand into nephrology and retinal diseases. Biogen outlines extensive board refreshment, with most independent directors appointed since 2019 and an independent chair structure transitioning to Dr. Maria C. Freire.
Executive compensation changes respond to 67.7% Say on Pay support in 2025, adding caps when revenue and EPS underperform, introducing a pipeline metric to performance stock units, raising the rTSR target to the 55th percentile, and tightening CEO bonus alignment to company results. The proxy also details corporate responsibility efforts, including more than $34.6 million in 2025 community contributions and progress on emissions and waste reduction.
Biogen Inc. launches a tender offer to acquire Apellis Pharmaceuticals for $41.00 per share plus a contingent value right. Purchaser Aspen Purchaser Sub, a Biogen subsidiary, offers $41.00 in cash per Apellis share and one non-transferable contingent value right per share for up to an aggregate $4.00 upon specified milestones under a Contingent Value Rights Agreement, each subject to the terms of the Offer to Purchase. Apellis had 128,007,815 shares outstanding as of April 9, 2026, with additional potential dilution from convertible notes of $93,897,000 (convertible at 25.3405 shares per $1,000) and awarded equity awards described in the filing. The offer and the Merger Agreement govern the transaction; the Offer to Purchase, Letter of Transmittal, and merger documents are incorporated by reference.
Biogen Inc. launches a tender offer to acquire Apellis Pharmaceuticals for $41.00 per share plus a contingent value right. Purchaser Aspen Purchaser Sub, a Biogen subsidiary, offers $41.00 in cash per Apellis share and one non-transferable contingent value right per share for up to an aggregate $4.00 upon specified milestones under a Contingent Value Rights Agreement, each subject to the terms of the Offer to Purchase. Apellis had 128,007,815 shares outstanding as of April 9, 2026, with additional potential dilution from convertible notes of $93,897,000 (convertible at 25.3405 shares per $1,000) and awarded equity awards described in the filing. The offer and the Merger Agreement govern the transaction; the Offer to Purchase, Letter of Transmittal, and merger documents are incorporated by reference.
Biogen Inc., through its wholly owned subsidiary Aspen Purchaser Sub, Inc., provided pre-commencement communications about a planned tender offer to acquire all outstanding shares of Apellis Pharmaceuticals, Inc. pursuant to the Agreement and Plan of Merger dated March 31, 2026.
The communication states the tender offer has not commenced and that formal offer materials will be filed on Schedule TO at commencement; it urges Apellis securityholders to review the eventual offer documents and the solicitation/recommendation statement on Schedule 14D-9.
Biogen Inc., through its wholly owned subsidiary Aspen Purchaser Sub, Inc., provided pre-commencement communications about a planned tender offer to acquire all outstanding shares of Apellis Pharmaceuticals, Inc. pursuant to the Agreement and Plan of Merger dated March 31, 2026.
The communication states the tender offer has not commenced and that formal offer materials will be filed on Schedule TO at commencement; it urges Apellis securityholders to review the eventual offer documents and the solicitation/recommendation statement on Schedule 14D-9.
Biogen Inc. disclosed that its first-quarter 2026 results will include approximately $34 million in acquired in-process research and development, upfront and milestone expense on a pre-tax basis. This charge is expected to reduce GAAP and non-GAAP net income by about $0.19 per diluted share for the quarter ended March 31, 2026.
These expenses relate to collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of in-process R&D. Biogen noted that quarterly results are preliminary and subject to closing procedures, and actual results may differ from current estimates.
Biogen’s subsidiary announced pre-commencement communications about a planned tender offer to acquire all outstanding shares of Apellis Pharmaceuticals under an Agreement and Plan of Merger dated March 31, 2026. The communication states the tender offer has not yet commenced and that formal offer materials will be filed on Schedule TO when the offer begins. It directs Apellis securityholders to read the forthcoming offer documents and the solicitation/recommendation statement on Schedule 14D-9 carefully and to obtain those materials from the SEC or company websites. The filing includes customary forward-looking disclaimers and identifies social media posts made on March 31, 2026 as an exhibit.
Biogen’s subsidiary announced pre-commencement communications about a planned tender offer to acquire all outstanding shares of Apellis Pharmaceuticals under an Agreement and Plan of Merger dated March 31, 2026. The communication states the tender offer has not yet commenced and that formal offer materials will be filed on Schedule TO when the offer begins. It directs Apellis securityholders to read the forthcoming offer documents and the solicitation/recommendation statement on Schedule 14D-9 carefully and to obtain those materials from the SEC or company websites. The filing includes customary forward-looking disclaimers and identifies social media posts made on March 31, 2026 as an exhibit.
BIOGEN INC. Chief Accounting Officer Sean Godbout exercised 181 restricted stock units into 181 shares of common stock on April 1, 2026. The RSUs, granted on April 1, 2025, vest in three equal yearly installments, and this transaction reflects one vesting event.
To cover tax obligations, 54 shares of common stock were withheld at a price of $183.78 per share, leaving a net increase of 127 shares. Following these compensation-related transactions, Godbout directly holds about 1,341.6667 shares of Biogen common stock, indicating a routine equity vesting and tax-withholding pattern rather than open-market trading.